Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 39
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O1889908772EN
Leaflet:

Download PDF Leaflet

Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016
Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively for Organophosphate and Carbamate Poisoning.

Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Organophosphate and Carbamate Poisoning Overview
Therapeutics Development
Pipeline Products for Organophosphate and Carbamate Poisoning - Overview
Pipeline Products for Organophosphate and Carbamate Poisoning - Comparative Analysis
Organophosphate and Carbamate Poisoning - Therapeutics under Development by Companies
Organophosphate and Carbamate Poisoning - Therapeutics under Investigation by Universities/Institutes
Organophosphate and Carbamate Poisoning - Pipeline Products Glance
Early Stage Products
Organophosphate and Carbamate Poisoning - Products under Development by Companies
Organophosphate and Carbamate Poisoning - Products under Investigation by Universities/Institutes
Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development
Countervail Corporation
Hager Biosciences, LLC
Organophosphate and Carbamate Poisoning - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AM-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galantamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PlantVax-1502-H-N - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RS-194B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate BuChE for Carbamate and Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Organophosphate and Carbamate Poisoning - Discontinued Products
Organophosphate and Carbamate Poisoning - Product Development Milestones
Featured News & Press Releases
Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 39

LIST OF TABLES

Number of Products under Development for Organophosphate and Carbamate Poisoning, H2 2016
Number of Products under Development for Organophosphate and Carbamate Poisoning - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corporation, H2 2016
Organophosphate and Carbamate Poisoning - Pipeline by Hager Biosciences, LLC, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Organophosphate and Carbamate Poisoning - Discontinued Products, H2 2016 36

LIST OF FIGURES

Number of Products under Development for Organophosphate and Carbamate Poisoning, H2 2016
Number of Products under Development for Organophosphate and Carbamate Poisoning - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Action, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: